Geriatric Medicine Through Understanding Age-Related Cardiac Energetic Remodeling

Abstract

With the global population aging rapidly, understanding the impact of age-related cardiac energetic remodeling has become essential in geriatric medicine. Age-associated changes in cardiac energy metabolism underlie many structural and functional alterations that increase cardiovascular disease susceptibility in older adults. This review synthesizes recent evidence on epidemiology, pathophysiology, clinical features, diagnostic strategies, and current management approaches, emphasizing mechanisms and practical implications for healthcare professionals managing elderly patients with cardiac disease. By elucidating how energetic remodeling contributes to geriatric cardiovascular syndromes, clinicians can optimize patient outcomes through tailored interventions and emerging therapies.

Introduction

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality among older adults. As life expectancy rises, clinicians increasingly encounter complex cardiac presentations in geriatric patients. A critical and often underappreciated driver of these age-related cardiac changes is energetic remodeling – encompassing alterations in substrate utilization, mitochondrial function, and bioenergetic efficiency within the aging heart. These metabolic shifts are closely linked to the pathogenesis of heart failure, ischemic heart disease, and arrhythmias in the elderly. This article explores the clinical relevance and mechanistic basis of age-related cardiac energetic remodeling, providing actionable insights for the care of older adults.

Epidemiology / Disease Burden

Globally, the proportion of individuals aged 65 years and above is projected to double by 2050, with a corresponding surge in age-related CVD. Heart failure with preserved ejection fraction (HFpEF), a phenotype strongly associated with aging, now accounts for over half of all heart failure cases. Epidemiological studies reveal that the prevalence of diastolic dysfunction, atrial fibrillation, and ischemic heart disease increases exponentially with age, attributed in part to cumulative energetic deficits. The burden of age-related cardiac disease is compounded by multimorbidity, polypharmacy, and frailty, highlighting the need for nuanced understanding of underlying mechanisms.

Pathophysiology

Aging induces profound changes in myocardial energetics. Mitochondrial dysfunction is central, characterized by reduced oxidative phosphorylation, increased reactive oxygen species (ROS) production, and impaired ATP generation. The aging heart shifts from fatty acid oxidation to greater reliance on glucose metabolism, yet insulin resistance and impaired glycolytic flux often limit compensatory capacity. These energetic derangements contribute to decreased contractile reserve, diastolic dysfunction, and increased arrhythmogenicity. Additionally, sirtuin and AMPK signaling pathways, key regulators of cardiac metabolism and autophagy, become dysregulated with age, further accelerating cardiomyocyte senescence and fibrosis.

Risk Factors

Several modifiable and non-modifiable risk factors influence the trajectory of cardiac energetic remodeling in older adults. Non-modifiable factors include chronological age, genetic predisposition, and sex, with postmenopausal women experiencing accelerated shifts in cardiac metabolism. Modifiable contributors encompass hypertension, diabetes mellitus, obesity, sedentary lifestyle, and chronic inflammation. Cumulative exposure to cardiotoxic agents (e.g., chemotherapeutics) and environmental toxins can exacerbate mitochondrial injury and energetic decline. Recognizing and addressing these risk factors is crucial for prevention and early intervention.

Clinical Features

Energetic remodeling manifests clinically as exercise intolerance, fatigue, and subclinical diastolic dysfunction, often preceding overt cardiac failure. Elderly patients may present with atypical or blunted symptoms due to altered autonomic function and comorbidities. Physical findings include elevated jugular venous pressure, pulmonary rales, and peripheral edema in advanced stages. Cognitive decline and sarcopenia may be exacerbated by compromised cardiac output and tissue perfusion. Early identification of subtle clinical features necessitates a high index of suspicion and comprehensive geriatric assessment.

Diagnosis

Diagnosis of age-related cardiac energetic remodeling relies on integrating clinical evaluation with advanced imaging and biomarker assessment. Echocardiography is pivotal for detecting diastolic dysfunction, left atrial enlargement, and myocardial strain abnormalities. Cardiac magnetic resonance (CMR) imaging, with tissue characterization and phosphorus MR spectroscopy, offers insights into myocardial energetics and fibrosis. Biomarkers such as NT-proBNP, high-sensitivity troponin, and novel mitochondrial-derived peptides provide adjunctive diagnostic value. Functional assessments, including cardiopulmonary exercise testing, can unmask subclinical disease by quantifying exercise capacity and circulatory reserve.

Treatment & Management

Management strategies target both modifiable risk factors and underlying energetic deficits. Optimization of blood pressure, glycemic control, and lipid profiles is foundational. Pharmacologic therapies such as ACE inhibitors, ARBs, beta-blockers, and mineralocorticoid receptor antagonists provide mortality benefits in select populations. SGLT2 inhibitors have demonstrated efficacy in reducing heart failure hospitalization, with evidence suggesting beneficial effects on cardiac metabolism. Lifestyle interventions, including tailored exercise programs and dietary modification (e.g., Mediterranean diet), support mitochondrial health and functional capacity. Multidisciplinary care addressing frailty and polypharmacy is essential for optimizing outcomes in the geriatric population.

Recent Advances / Emerging Therapies

Novel therapies targeting cardiac energetics are in active development. Agents enhancing mitochondrial biogenesis (e.g., PGC-1α agonists) and modulators of sirtuin/AMPK pathways show promise in preclinical studies. Metabolic modulators such as trimetazidine and perhexiline, which shift substrate utilization toward glucose, are being evaluated for symptomatic benefit in elderly patients with ischemic or non-ischemic cardiomyopathy. Gene therapies and mitochondrial transfer techniques represent future avenues for restoring bioenergetic capacity. Precision medicine approaches leveraging omics-based profiling may enable individualized risk stratification and therapeutic targeting.

Guideline Recommendations

Contemporary guidelines emphasize the need for individualized, mechanism-based care in geriatric cardiology. The American College of Cardiology and European Society of Cardiology recommend comprehensive assessment of comorbidities and functional status, alongside standard heart failure therapies. Guidelines increasingly acknowledge the role of metabolic risk factor modification and endorse the use of SGLT2 inhibitors for older adults with heart failure and preserved ejection fraction. The integration of geriatric principles, such as deprescribing and shared decision-making, is critical for balancing risks and benefits in complex elderly populations.

Conclusion

Age-related cardiac energetic remodeling represents a fundamental pathophysiologic process underlying cardiovascular disease in older adults. Understanding its mechanisms and clinical consequences enables targeted interventions that address both traditional and emerging risk factors. Recent advances in diagnostics and therapeutics hold promise for improving outcomes in this growing and vulnerable patient population. Clinicians must remain vigilant for subtle presentations and apply mechanism-based management grounded in the latest evidence and guideline recommendations to optimize cardiac health in the elderly.